Sfoglia per Autore

opzioni
Mostrati risultati da 1 a 20 di 35
Titolo Data di pubblicazione Autore(i) File
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 2010 Simona Rolla; Valentina Bardina; Marinella Clerico; Luca Durelli;Francesco Novelli
T helper 22 increase in multiple sclerosis patints: phenotypical and functional characterization 2010 Rolla S; Bardina V; Clerico M; Durelli L; Novelli F
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 2010 Simona Rolla; Valentina Bardina; Marinella Clerico; Luca Durelli; Francesco Novelli
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 2010 Simona Rolla; Laura Conti; Raffaele De Palma; Daniela Boselli; Valentina Bardina; Gabriella Rodolico; Olli Silveinnonen; Marinella Clerico; Luca Durelli; Francesco Novelli
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 2011 Simona Rolla ; Marinella Clerico; Valentina Bardina; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Multiparametric analysis of Th17 and Th22 cells discloses their pathogenicity in human multiple sclerosis 2012 Rolla, S.; Bardina, V.; Clerico, M.; Durelli L. and Novelli F.
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Kovarova,I.; Clerico, M.; Durelli, L.
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Phenotypical and functional characterization of T Helper 22 cells inMultiple Sclerosis patients 2012 S. Rolla; M. Clerico; V. Bardina; P. Quaglino; L. Durelli; F. Novelli
THE ACUTE-PHASE PROTEIN HEMOPEXIN IS A NEGATIVE REGULATOR OF TH17 RESPONSE AND EXPERIMENTAL AUTOIMMUNE ENCEPHALOMIELITIS DEVELOPMENT 2013 Rolla S.; Ingoglia G.; Bardina V.; Silengo L.; Altruda F.; Novelli F.; Tolosano E.
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 2013 De Mercanti S; Clerico M; Rolla S; Cucci A; Novelli F; Taverna D; Bardina V; Piazza F; Gibbin M; Vargas J; Vladic A; Habek M; Adamec B; Brinar V; Cocco E; Frau J; Annovazzi P; Horakova D; Kovarova I; Durelli L
Role of Th22 expansion in multiple sclerosis disease activity 2013 De Mercanti S; Clerico M; Rolla S; Bardina V; Quaglino P; De Palma R; Gned D; Novelli F; Durelli L
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  2014 S. Rolla;V. Bardina;S. De Mercanti;P. Quaglino;R. De Palma;D. Gned;D. Brusa;L. Durelli;F. Novelli;M. Clerico
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 2014 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 2015 De Mercanti, S.F.; Rolla, S.; Cucci, A.; Bardina, V.; Vacca, A.; Cocco, E.; Vladic, A.; Soldo-Butkovic, S.; Habek, M.; Adamec, I.; Horakova, D.; Annovazzi, P.; Edan, G.; Novelli, F.; Durelli, L.; Clerico, M.
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 2015 De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Vacca, A; Cocco, E; Vladic, A; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Edan, G; Durelli, L; Clerico, M
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice 2016 Rolla, Simona; Alchera, Elisa; Imarisio, Chiara; Bardina, Valentina; Valente, Guido; Cappello, Paola; Mombello, Cristina; Follenzi, Antonia; Novelli, Francesco; Carini, Rita
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 2016 De Mercanti, Stefania; Rolla, Simona; Cucci, Angele; Bardina, Valentina; Cocco, Eleonora; Vladic, Anton; Soldo-Butkovic, Silva; Habek, Mario; Adamec, Ivan; Horakova, Dana; Annovazzi, Pietro; Novelli, Francesco; Durelli, Luca; Clerico, Marinella
Mostrati risultati da 1 a 20 di 35
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile